Skip to main content
SpringerPlus

Table 2 Headache characteristics before and after treatment with cinnarizine

From: Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study

Variable

Total vertigo population (n = 40)

Subgroups

Vestibular migraine (n = 24)

Migraine with brainstem aura (n = 16)

p-value1

Monthly frequency of migraine attacks (mean ± SD)

    

 At baseline

4.02 ± 1.2

3.92 ± 0.9

4.19 ± 1.5

0.845

 12-week treatment period

    

  1st 4-week

2.35 ± 1.1*

1.92 ± 0.6*

3.00 ± 1.3*

0.001

  2nd 4-week

1.30 ± 1.2*

0.71 ± 0.8*

2.19 ± 1.0*

<0.001

  3rd 4-week

1.10 ± 0.9*

0.75 ± 0.7*

1.62 ± 1.0*

0.004

Monthly duration of migraine attacks, hours (mean ± SD)

    

 At baseline

26.20 ± 15.3

23.58 ± 15.8

30.12 ± 14.1

0.011

 12-week treatment period

    

  1st 4-week

14.78 ± 6.3*

13.88 ± 7.0*

16.12 ± 4.9*

0.066

  2nd 4-week

5.68 ± 5.1*

3.46 ± 4.1*

9.00 ± 4.6*

0.001

  3rd 4-week

4.18 ± 3.6*

2.58 ± 3.0*

6.56 ± 3.2*

<0.001

Monthly intensity of migraine attacks, VAS (median, Max.-Min.)

    

 At baseline

8 (7–10)

8 (7–10)

9 (7–10)

0.087

 12-week treatment period

    

  1st 4-week

6 (4–10)*

5 (4–9)*

7 (5–10)*

0.005

  2nd 4-week

3 (0–9)*

1 (0–7)*

5 (2–9)*

<0.001

  3rd 4-week

3 (0–8)*

1 (0–5)*

4 (2–8)*

<0.001

  1. VAS Visual Analog Scale.
  2. *p < 0.05 compared with baseline.
  3. 1p-value for comparison between vestibular migraine and migraine with brainstem aura.
Back to article page